Microbix Biosystems Inc. (MBXBF)
Microbix Biosystems Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mississauga, ON, CA. The stock last traded at $0.22, up 0.00% on the session, giving a market capitalisation of $30.3M. On trailing twelve-month figures it carries a trailing P/E of -7.56, a net margin of -38.6%. Its beta of 0.57 implies it has historically moved less than the broad market.
Microbix Biosystems Inc. is a life sciences enterprise that invents and markets unique biological and technological innovations designed to improve human health and well-being. Operating across North America, Europe, and other international markets, the company primarily produces essential biological reagents for the diagnostics industry. This includes antigens for immunoassays and its proprietary Quality Assessment and Proficiency (QAP) products. These QAPs are crucial for supporting clinical laboratory proficiency testing, aiding in assay development and validation, and streamlining lab workflows. Furthermore, Microbix leverages its biological knowledge and infrastructure to create other specialized products, such as its DxTM (viral transport medium) for stabilizing patient samples for laboratory analysis, and Kinlytic Urokinase, a biologic drug for treating blood clots. Its QAP offerings are sold to laboratory accreditation organizations, diagnostic firms, and clinical laboratories via a network of regional distributors. Founded in 1988, Microbix Biosystems Inc. is headquartered in Mississauga, Canada.
Microbix Biosystems Inc. is most often compared with the following Healthcare names: